Completed PHASE4 INTERVENTIONAL NCT00240838

An Effectiveness and Safety Study Comparing Acetaminophen (3900 mg/Day) to Ibuprofen (1200 mg/Day) in the Treatment of Post-Race Muscle Soreness.

A Randomized, Double-Blind Study Evaluating Acetaminophen Extended Release Caplets (3900 mg/Day) and Ibuprofen (1200 mg/Day) in the Treatment of Post-Race Muscle Soreness.

Sponsor: Johnson & Johnson Consumer and Personal Products Worldwide

Conditions Pain

Interventions acetaminophen extended release caplets

Updated 5 times since 2017 Last updated: Jun 28, 2011 Started: May 31, 2003 Completion: Jun 30, 2003

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on Pain, this trial is completed. The trial is conducted by Johnson & Johnson Consumer and Personal Products Worldwide and has accumulated 5 data snapshots since 2003. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

May 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Johnson & Johnson Consumer and Personal Products Worldwide

Data source: Johnson & Johnson Consumer and Personal Products Worldwide

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.